JP2022501327A5 - - Google Patents
Info
- Publication number
- JP2022501327A5 JP2022501327A5 JP2021512742A JP2021512742A JP2022501327A5 JP 2022501327 A5 JP2022501327 A5 JP 2022501327A5 JP 2021512742 A JP2021512742 A JP 2021512742A JP 2021512742 A JP2021512742 A JP 2021512742A JP 2022501327 A5 JP2022501327 A5 JP 2022501327A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- pharmaceutically acceptable
- acceptable salt
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728556P | 2018-09-07 | 2018-09-07 | |
| US62/728,556 | 2018-09-07 | ||
| PCT/US2019/049784 WO2020051356A1 (en) | 2018-09-07 | 2019-09-05 | Imidazoquinoline compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022501327A JP2022501327A (ja) | 2022-01-06 |
| JP2022501327A5 true JP2022501327A5 (enExample) | 2022-07-04 |
Family
ID=69722888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512742A Pending JP2022501327A (ja) | 2018-09-07 | 2019-09-05 | イミダゾキノリン化合物およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210214354A1 (enExample) |
| EP (2) | EP4306523A3 (enExample) |
| JP (1) | JP2022501327A (enExample) |
| KR (1) | KR20210074290A (enExample) |
| CN (1) | CN113164460A (enExample) |
| AU (1) | AU2019335366A1 (enExample) |
| CA (1) | CA3111786A1 (enExample) |
| ES (1) | ES2963112T3 (enExample) |
| WO (1) | WO2020051356A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3092256T3 (da) | 2014-01-10 | 2022-06-20 | Birdie Biopharmaceuticals Inc | Forbindelser og sammensætninger til immunterapi |
| CN121243402A (zh) | 2014-07-09 | 2026-01-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1组合 |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CA3067268A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| US20230248835A1 (en) * | 2020-07-08 | 2023-08-10 | Purdue Research Foundation | Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US689338A (en) * | 1901-03-29 | 1901-12-17 | Nat Faucet Company | Tapping-bung. |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| JP2007504232A (ja) * | 2003-09-05 | 2007-03-01 | アナディス ファーマシューティカルズ インク | Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与 |
| CN101056877B (zh) * | 2004-09-14 | 2010-06-09 | 诺华疫苗和诊断公司 | 咪唑并喹啉化合物 |
| US8728486B2 (en) * | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| US9034336B2 (en) * | 2011-08-30 | 2015-05-19 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
| PT3134402T (pt) * | 2014-04-22 | 2020-07-02 | Hoffmann La Roche | Compostos de 4-amino-imidazoquinolina |
| CN121243402A (zh) * | 2014-07-09 | 2026-01-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1组合 |
| CN105233291A (zh) * | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| CN115350279A (zh) * | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
-
2019
- 2019-09-05 AU AU2019335366A patent/AU2019335366A1/en not_active Abandoned
- 2019-09-05 EP EP23188546.8A patent/EP4306523A3/en not_active Withdrawn
- 2019-09-05 ES ES19858183T patent/ES2963112T3/es active Active
- 2019-09-05 JP JP2021512742A patent/JP2022501327A/ja active Pending
- 2019-09-05 KR KR1020217010120A patent/KR20210074290A/ko not_active Ceased
- 2019-09-05 WO PCT/US2019/049784 patent/WO2020051356A1/en not_active Ceased
- 2019-09-05 CA CA3111786A patent/CA3111786A1/en active Pending
- 2019-09-05 US US17/274,136 patent/US20210214354A1/en not_active Abandoned
- 2019-09-05 EP EP19858183.7A patent/EP3846807B1/en active Active
- 2019-09-05 CN CN201980068724.0A patent/CN113164460A/zh active Pending